Raymond James Financial Inc. Invests $208,000 in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Raymond James Financial Inc. purchased a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 135,722 shares of the biotechnology company's stock, valued at approximately $208,000. Raymond James Financial Inc. owned about 0.09% of Heron Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of HRTX. JPMorgan Chase & Co. lifted its stake in shares of Heron Therapeutics by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock worth $411,000 after acquiring an additional 154,487 shares during the period. Principal Financial Group Inc. grew its holdings in Heron Therapeutics by 10.6% in the fourth quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock worth $174,000 after purchasing an additional 10,909 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Heron Therapeutics by 22.2% in the fourth quarter. Wells Fargo & Company MN now owns 74,763 shares of the biotechnology company's stock valued at $114,000 after buying an additional 13,568 shares in the last quarter. Congress Park Capital LLC lifted its stake in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock valued at $3,757,000 after buying an additional 477,417 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Heron Therapeutics by 29.8% during the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company's stock valued at $434,000 after purchasing an additional 50,109 shares in the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Stock Up 8.7%

Shares of NASDAQ HRTX traded up $0.15 during midday trading on Thursday, hitting $1.87. The stock had a trading volume of 1,893,196 shares, compared to its average volume of 2,335,023. The company has a market cap of $285.29 million, a P/E ratio of -10.39 and a beta of 1.33. The business's 50 day moving average is $2.15 and its 200-day moving average is $1.82. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million for the quarter, compared to analysts' expectations of $37.08 million. As a group, analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HRTX has been the topic of several research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, April 11th. StockNews.com cut shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.